This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Adenoid cystic carcinoma of the salivary gland

Authoring team

The adenoid cystic carcinoma is the most common tumour among minor salivary glands, and accounts for about 30% of all malignant salivary gland tumours. About 70% arise in the oral cavity. It is uncommon in the parotid.

The tumour has a characteristic cribriform, i.e. sieve-like, microscopic appearance caused by numerous small spaces in a tightly-packed tumour cell mass. There is a great propensity for neural spread causing neuropathy and pain disproportionate to the size of the lesion.

It is highly invasive with early regional and systemic metastasis; the instance of metastases is up to 50% and increases with time. Treatment is by primary radical surgery which usually destroys the facial nerve.

Radiotherapy offers little benefit. Patients have a protracted illness. Recurrence is common and may occur as long as 15 years after apparently successful eradication. Those with distant metastases may survive for 5 or more years.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.